- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02152878
Transcranial Direct Current Stimulation for the Treatment of Bipolar Depression (TDCS-BD)
November 20, 2016 updated by: Andre Brunoni, University of Sao Paulo
Non-invasive brain stimulation therapies have been increasingly investigated in recent years as a treatment for neuropsychiatric disorders, particularly mood disorders.
They are particularly appealing since many patients are either refractory or present side effects to standard pharmacological regimens.
TDCS (transcranial direct current stimulation).
a novel non- pharmacological brain stimulation technique, might help in overcoming some of these issues, since it has low cost, high portability and it is relatively easy to use.
TDCS consists in applying a weak, direct current through two electrodes placed over the scalp; the anode and the cathode increasing and decreasing cortical excitability during and beyond the period of stimulation.
It is also a safe technique with only mild adverse effects described.
Previous studies, some of them from our group, have described that tDCS is an effective technique for major depression.
However, the role of tDCS as a treatment for bipolar depression (BD) has been insufficiently investigated.
Therefore, our aim is to address the antidepressant effects of tDCS in BD in a randomized, sham- controlled trial in a refractory sample.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
BD represents the greatest burden on patients with bipolar disorder, since the depressive episodes are the most frequent and also particularly associated with suicide 7. BD treatment is controversial, with some stricter guidelines recommending only lithium, lamotrigine and quetiapine as a first-treatment, whereas others allow the use of antidepressants (which can increase manic switch and should be used in association with mood stabilizers) and other anticonvulsants and antipsychotics 8.
For refractory BD the available level I evidence is very scarce, with only seven studies exploring this issue hitherto 9. Therefore, the importance of this study proposal is justified considering the burden of the disease, the paucity of current therapeutic studies and the promising results presented for tDCS in unipolar disorder.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
São Paulo, Brazil, 05508000
- University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- bipolar depressed (type I, II or not otherwise specified) participants with symptoms in spite of an adequate treatment course with mood stabilizers.
- the depressive episode has to be of at least moderate intensity (baseline HDRS>=16)
- read and understand Portuguese
Exclusion Criteria:
- other neuropsychiatric conditions, such as schizophrenia, substance dependence, dementias, traumatic brain injury, epilepsy and so forth (although participants with anxiety disorders can be included whether the primary diagnosis is BDD);
- mixed states, defined as simultaneously presenting (hypo)manic symptoms with a Young Manic Rating Scale (YMRS) > 8;
- pregnancy;
- specific contra-indications to tDCS;
- severe/life-threatening clinical conditions. Participants will have to be drug-free or at stable drug regimen for at least 6 weeks prior to trial onset. Benzodiazepine drugs will be allowed, although only at low doses (less than 20mg/day of diazepam or equivalent).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active stimulation
Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
|
For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system).
We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day.
This montage is known as "bifrontal" setup and has been previously used in major depression trials
|
Placebo Comparator: Sham stimulation
For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
|
For sham tDCS, the device will be turned off after 30 seconds of stimulation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hamilton Scale for Depression, 17 items
Time Frame: week 0 (baseline), week 2, week 4 and week 6 (endpoint)
|
Continuous measure (score change)
|
week 0 (baseline), week 2, week 4 and week 6 (endpoint)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Montgomery-Asberg Depression Rating Scale
Time Frame: week 0 (baseline), week 2, week 4 and week 6 (endpoint)
|
Continuous measure (score changes)
|
week 0 (baseline), week 2, week 4 and week 6 (endpoint)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Goerigk S, Cretaz E, Sampaio-Junior B, Vieira ELM, Gattaz W, Klein I, Lafer B, Teixeira AL, Carvalho AF, Lotufo PA, Bensenor IM, Buhner M, Padberg F, Brunoni AR. Effects of tDCS on neuroplasticity and inflammatory biomarkers in bipolar depression: Results from a sham-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 8;105:110119. doi: 10.1016/j.pnpbp.2020.110119. Epub 2020 Oct 4.
- Tortella G, Sampaio-Junior B, Moreno ML, Moffa AH, da Silva AF, Lafer B, Lotufo PA, Gattaz W, Borrione L, Machado-Vieira R, Goerigk S, Bensenor IM, Brunoni AR. Cognitive outcomes of the bipolar depression electrical treatment trial (BETTER): a randomized, double-blind, sham-controlled study. Eur Arch Psychiatry Clin Neurosci. 2021 Feb;271(1):93-100. doi: 10.1007/s00406-020-01121-2. Epub 2020 Mar 27.
- Sampaio-Junior B, Tortella G, Borrione L, Moffa AH, Machado-Vieira R, Cretaz E, Fernandes da Silva A, Fraguas R, Aparicio LV, Klein I, Lafer B, Goerigk S, Bensenor IM, Lotufo PA, Gattaz WF, Brunoni AR. Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018 Feb 1;75(2):158-166. doi: 10.1001/jamapsychiatry.2017.4040.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
November 1, 2016
Study Registration Dates
First Submitted
May 29, 2014
First Submitted That Met QC Criteria
May 30, 2014
First Posted (Estimate)
June 2, 2014
Study Record Updates
Last Update Posted (Estimate)
November 22, 2016
Last Update Submitted That Met QC Criteria
November 20, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BETTER
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Bipolar
-
University Health Network, TorontoCompletedBipolar Disorder | Bipolar Depression | Bipolar I Depression | Bipolar II DepressionCanada
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
Forest LaboratoriesGedeon Richter Ltd.CompletedDepression, BipolarUnited States, Ukraine, Bulgaria, Canada, Colombia, Russian Federation
-
Queen's UniversityPfizer; Providence Health & Services; MDS Pharma ServicesCompletedDepression, BipolarCanada
-
Ewha Womans University Mokdong HospitalWithdrawnDepression, BipolarKorea, Republic of
-
Mclean HospitalTerminatedBipolar Depression Depressed PhaseUnited States
-
AstraZenecaCompletedAcute Bipolar DepressionBrazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
-
Valerie TaylorUniversity Health Network, TorontoActive, not recruitingBipolar DepressionCanada
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteCompletedBipolar DepressionIreland
-
Astellas Pharma IncCompleted
Clinical Trials on Active stimulation
-
Tianjin Anding HospitalChinese Academy of SciencesEnrolling by invitationSchizophrenia Negative TypeChina
-
BrainsGateTerminatedAcute Ischemic StrokeSpain, Germany, United States
-
Nottingham University Hospitals NHS TrustUniversity of Nottingham; Neurotherapeutics LtdCompletedTourette Syndrome | Chronic Tic DisorderUnited Kingdom
-
Centre Hospitalier Henri LaboritMinistry of Health, FranceCompletedObsessive-Compulsive DisorderFrance
-
University Hospital, RouenMinistry of Health, FranceCompletedFecal IncontinenceFrance
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS); MedtronicRecruitingParkinson Disease | Dystonia | Essential TremorUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAxial SpondyloarthritisFrance
-
VA Office of Research and DevelopmentCompleted
-
Institut National de la Santé Et de la Recherche...Completed
-
Andrew KrystalRecruitingMajor Depressive DisorderUnited States